Written question – Strategy for European life sciences – E-004156/2025

Question for written answer  E-004156/2025
to the Commission
Rule 144
Ton Diepeveen (PfE)

The strategy for life sciences states that various initiatives, including the EU startup and scaleup strategy[1], the upcoming EU Biotech Act and the medical countermeasures strategy[2], will contribute to reaching the aims set out in the strategy for European life sciences.[3]

• 1.Why has the Commission launched a new strategy when the various European initiatives mentioned above are still in the preparation phase?
• 2.Following on from the previous question: on what basis has the Commission reached the conclusion that both investment and new regulations are necessary, when no concrete results are yet available for the other European initiatives?

Submitted: 22.10.2025

• [1] https://research-and-innovation.ec.europa.eu/document/download/2f76a0df-b09b-47c2-949c-800c30e4c530_en
• [2] https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera/preparedness/medical-countermeasures-strategy_en
• [3] https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52025DC0525